Literature DB >> 9288173

Mapping the peripheral benzodiazepine receptor binding site by conformationally restrained derivatives of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3- isoquinolinecarboxamide (PK11195).

A Cappelli1, M Anzini, S Vomero, P G De Benedetti, M C Menziani, G Giorgi, C Manzoni.   

Abstract

A synthetic-computational approach to the study of the binding site of peripheral benzodiazepine receptor (PBR) ligands related to 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxam ide (PK11195, 1) within their receptor has been developed. A wide series of conformationally restrained derivatives of 1 has been designed with the aim of probing the PBR binding site systematically. The synthesis of these compounds involves palladium-catalyzed coupling and amidation as the key steps. Twenty-nine rigid and semirigid derivatives of 1 were tested in binding studies using [3H]-1, and most of these showed PBR affinities in the nanomolar range. The essential role of the carbonyl moiety as a primary pharmacophoric element in the recognition by and the binding to PBR has been confirmed, and the restricted range of the carbonyl orientations, which characterizes the most potent ligands, points to a specific hydrogen-bonding interaction, mainly directed by the geometrical factors, when the electronic ones are fulfilled. Moreover, the fundamental importance of the short-range dispersive interactions in the modulation of the binding affinity and, hence, in the stabilization of the ligand-receptor complex, emerged from the QSAR models reported.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288173     DOI: 10.1021/jm960516m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Development of a unique 3D interaction model of endogenous and synthetic peripheral benzodiazepine receptor ligands.

Authors:  N Cinone; H D Hötje; A Carotti
Journal:  J Comput Aided Mol Des       Date:  2000-11       Impact factor: 3.686

2.  Translocator protein ligands based on N-methyl-(quinolin-4-yl)oxypropanamides with properties suitable for PET radioligand development.

Authors:  Chad Brouwer; Kimberly J Jenko; Sami S Zoghbi; Cheryl L Morse; Robert B Innis; Victor W Pike
Journal:  Eur J Med Chem       Date:  2016-08-25       Impact factor: 6.514

3.  Solution structures of the prototypical 18 kDa translocator protein ligand, PK 11195, elucidated with 1H/13C NMR spectroscopy and quantum chemistry.

Authors:  Yong-Sok Lee; Fabrice G Siméon; Emmanuelle Briard; Victor W Pike
Journal:  ACS Chem Neurosci       Date:  2012-02-14       Impact factor: 4.418

4.  A novel 18F-labelled high affinity agent for PET imaging of the translocator protein.

Authors:  Adele Blair; Filip Zmuda; Gaurav Malviya; Adriana A S Tavares; Gilles D Tamagnan; Anthony J Chalmers; Deborah Dewar; Sally L Pimlott; Andrew Sutherland
Journal:  Chem Sci       Date:  2015-05-27       Impact factor: 9.825

Review 5.  The 18-kDa Translocator Protein PET Tracers as a Diagnostic Marker for Neuroinflammation: Development and Current Standing.

Authors:  Priya Singh; Anupriya Adhikari; Deepika Singh; Chandraprakash Gond; Anjani Kumar Tiwari
Journal:  ACS Omega       Date:  2022-04-18

6.  Development of N-methyl-(2-arylquinolin-4-yl)oxypropanamides as leads to PET radioligands for translocator protein (18 kDa).

Authors:  Chad Brouwer; Kimberly Jenko; Sami S Zoghbi; Robert B Innis; Victor W Pike
Journal:  J Med Chem       Date:  2014-07-01       Impact factor: 7.446

7.  Quantification of Macrophage-Driven Inflammation During Myocardial Infarction with 18F-LW223, a Novel TSPO Radiotracer with Binding Independent of the rs6971 Human Polymorphism.

Authors:  Mark G MacAskill; Agne Stadulyte; Lewis Williams; Timaeus E F Morgan; Nikki L Sloan; Carlos J Alcaide-Corral; Tashfeen Walton; Catriona Wimberley; Chris-Anne McKenzie; Nick Spath; William Mungall; Ralph BouHaidar; Marc R Dweck; Gillian A Gray; David E Newby; Christophe Lucatelli; Andrew Sutherland; Sally L Pimlott; Adriana A S Tavares
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 11.082

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.